Combination of mRNA-4157 With Pembrolizumab Improves Survival in Melanoma

Source: Targeted Oncology, June 2023

In the phase 2 KEYNOTE-942 trial (NCT03897881), mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) led to a reduced risk of developing distant metastasis or death by approximately 65% vs with pembrolizumab alone as adjuvant therapy in patients with resected melanoma at high risk of recurrence, according to findings presented at the 2023 ASCO Annual Meeting.

The median follow-up was 23 months for mRNA-4157 plus pembrolizumab and 24 months for pembrolizumab monotherapy. The 18-month distant metastasis-free survival (DMFS) rate was 91.8% with the combination vs 76.8% with pembrolizumab alone (HR, 0.347; 95% CI, 0.145-0.828; P = .0063).

“mRNA-4157-P201/KEYNOTE-942 is the first randomized trial to demonstrate improvement in recurrence-free survival [RFS] and distant metastasis-free survival [DMFS] with an individualized neoantigen therapy approach,” lead study author Muhammad Adnan Khattak, PhD, FRACP, MBBS, One Clinical Research and Edith Cowan University in Joondalup, Australia, said in a presentation of the data.